Anterogen.Co.,Ltd. (KOSDAQ:065660)

South Korea flag South Korea · Delayed Price · Currency is KRW
37,100
+900 (2.49%)
At close: Dec 5, 2025
132.31%
Market Cap 371.23B
Revenue (ttm) 7.32B
Net Income (ttm) -1.91B
Shares Out 10.01M
EPS (ttm) -193.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 202,285
Average Volume 78,591
Open 36,200
Previous Close 36,200
Day's Range 34,700 - 37,900
52-Week Range 14,810 - 37,900
Beta 0.36
RSI 87.30
Earnings Date n/a

About Anterogen.Co.,Ltd.

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn’s fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 065660
Full Company Profile

Financial Performance

In 2024, Anterogen.Co.,Ltd.'s revenue was 6.93 billion, an increase of 6.66% compared to the previous year's 6.50 billion. Losses were -2.29 billion, -19.29% less than in 2023.

Financial Statements

News

There is no news available yet.